Per‐ and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data From the Osteoarthritis Initiative
We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.
Authors
- Mary B. Roberts (ORCID: https://orcid.org/0000-0001-5509-5818)
- Jérémie Sellam (ORCID: https://orcid.org/0000-0002-1814-6003)
- Abby F. Fleisch (ORCID: https://orcid.org/0000-0002-2789-6412)
- Lisa B. Rokoff
- Jeffrey B. Driban (ORCID: https://orcid.org/0000-0001-6098-4273)
- Shawn O'Leary
- Charles B. Eaton (ORCID: https://orcid.org/0000-0002-7723-9461)
- Alice Courties (ORCID: https://orcid.org/0000-0001-8122-701X)
- I.K. Haugen (ORCID: https://orcid.org/0000-0001-7810-2216)
- Zhijin Carrie Xu
- Colleen Lestician
- Bing Lu
- Timothy E. McAlindon
- Zhihua Tina Fan
- Diana Mathes
Institutions
- UMass Memorial Health Care (US)
- Maine Medical Center (US)
- New Jersey Department of Health (US)
- Inserm (FR)
- University of Massachusetts Chan Medical School (US)
- Brown University (US)
- Memorial Hospital of Rhode Island (US)
- Sorbonne Université (FR)
- MaineHealth (US)
- Diakonhjemmet Hospital (NO)
- Maine Medical Center (US)
- Centre de Recherche Saint-Antoine (FR)
- UMass Memorial Medical Center (US)
- UConn Health (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1002/art.70026
- Primary Topic
- Per- and polyfluoroalkyl substances research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Pfizer
- GlaxoSmithKline
- Novartis Pharmaceuticals Corporation
- National Institutes of Health